NCT00782613

Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis

Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Wafety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Synvista Therapeutics, Inc · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study will be to evaluate the efficacy of topical ALT-2074 applied twice daily for 28 days for treatment of chronic plaque psoriasis in adult subjects. The secondary objective will be to evaluate the safety of topical ALT-2074 applied twice daily for 28 days for treatment of chronic plaque psoriasis in adult subjects. Tertiary objectives will be to provide visual documentation of the improvement of psoriatic plaques treated with ALT-2074 using digital photography, and to determine the extent of systemic absorption of topically applied ALT-2074 based on a pharmacokinetic measurement of blood concentration.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	4,4-dimethyl-benziso-2H-selenazine	ALT-2074 in a 0.5% cream formulation
DRUG	Placebo	Placebo in a cream formulation

Timeline

• Start date: 2008-11-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2008-10-31
• Last updated: 2009-01-30

Locations

3 sites across 1 country: Israel